| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Basic Science Investigations |
Endocyte, Inc., West Lafayette, Indiana
Our group previously reported on the synthesis and characterization of a novel 99mTc-based folate-peptide chelator called EC20. This agent was found to bind folate receptor (FR)–positive cells and tissues with high affinity and was deemed useful for radiodiagnostic applications. In this study, we investigated the effect of D-amino acid substitution within EC20 on its tissue biodistribution. Expanded in vivo studies were also performed with unmodified 99mTc-EC20 to determine the effect of tumor FR expression, tumor size, tumor location, route of dose administration, and rodent diet on the agent’s tissue biodistribution pattern. Methods: EC20 and EC53, the all-D-isomer of EC20, were synthesized and radiolabeled with 99mTc. The relative affinity of EC53 to the FR with respect to EC20 was then determined in cultured tumor cells. The ability of 99mTc-EC20 and 99mTc-EC53 to target tumors in vivo was examined using BALB/c mice with subcutaneously inoculated M109 or 4T1 cells, yielding 0.1- to 0.5-g tumors in 20 d. Results: The D-amino acid substitutions of EC20 were found to reduce the uptake of the agent into tumor and major organs. Subsequent studies using the original 99mTc-EC20 agent confirmed that its net tumor uptake was specific and proportional to FR expression levels in tumor cells as well as linear with respect to the overall tumor size. Further, 99mTc-EC20 uptake was found to be independent of both solid tumor location (intraperitoneal vs. subcutaneous) and the route of administration (intraperitoneal vs. intravenous). Interestingly, leucovorin supplementation of a commonly used folate-deficient laboratory chow had no effect on the agent’s overall tissue biodistribution pattern. But, tumor-to-nontumor ratios could be increased up to 2.7-fold when 1 equivalent of free folic acid was coinjected with 99mTc-EC20. Conclusion: Taken together, these results confirm that 99mTc-EC20 has the potential to be a clinically useful noninvasive radiodiagnostic agent for detecting the locus of FR–positive cancers.
Key Words: folate receptor • tumor targeting • endocytosis • 99mTc • tumor imaging
This article has been cited by other articles:
|
|
 |
|
  W. Xia, A. R. Hilgenbrink, E. L. Matteson, M. B. Lockwood, J.-X. Cheng, and P. S. Low A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages Blood, January 8, 2009; 113(2): 438 - 446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Leamon, J. A. Reddy, M. Vetzel, R. Dorton, E. Westrick, N. Parker, Y. Wang, and I. Vlahov Folate Targeting Enables Durable and Specific Antitumor Responses from a Therapeutically Null Tubulysin B Analogue Cancer Res., December 1, 2008; 68(23): 9839 - 9844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Leamon, J. A. Reddy, R. Dorton, A. Bloomfield, K. Emsweller, N. Parker, and E. Westrick Impact of High and Low Folate Diets on Tissue Folate Receptor Levels and Antitumor Responses Toward Folate-Drug Conjugates J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 918 - 925. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Fisher, B. A. Siegel, S. L. Edell, N. M. Oyesiku, D. E. Morgenstern, R. A. Messmann, and R. J. Amato Exploratory Study of 99mTc-EC20 Imaging for Identifying Patients with Folate Receptor-Positive Solid Tumors J. Nucl. Med., June 1, 2008; 49(6): 899 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Muller, R. Schibli, E. P. Krenning, and M. de Jong Pemetrexed Improves Tumor Selectivity of 111In-DTPA-Folate in Mice with Folate Receptor-Positive Ovarian Cancer J. Nucl. Med., April 1, 2008; 49(4): 623 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Muller, F. Forrer, R. Schibli, E. P. Krenning, and M. de Jong SPECT Study of Folate Receptor-Positive Malignant and Normal Tissues in Mice Using a Novel 99mTc-Radiofolate J. Nucl. Med., February 1, 2008; 49(2): 310 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. He, H. Wang, L. C. Hartmann, J.-X. Cheng, and P. S. Low In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry PNAS, July 10, 2007; 104(28): 11760 - 11765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Reddy, E. Westrick, H. K.R. Santhapuram, S. J. Howard, M. L. Miller, M. Vetzel, I. Vlahov, R. V.J. Chari, V. S. Goldmacher, and C. P. Leamon Folate Receptor-Specific Antitumor Activity of EC131, a Folate-Maytansinoid Conjugate Cancer Res., July 1, 2007; 67(13): 6376 - 6382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Reddy, R. Dorton, E. Westrick, A. Dawson, T. Smith, L.-C. Xu, M. Vetzel, P. Kleindl, I. R. Vlahov, and C. P. Leamon Preclinical Evaluation of EC145, a Folate-Vinca Alkaloid Conjugate Cancer Res., May 1, 2007; 67(9): 4434 - 4442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Muller, M. Bruhlmeier, P. A. Schubiger, and R. Schibli Effects of Antifolate Drugs on the Cellular Uptake of Radiofolates In Vitro and In Vivo J. Nucl. Med., December 1, 2006; 47(12): 2057 - 2064. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Lu, L.-C. Xu, N. Parker, E. Westrick, J. A. Reddy, M. Vetzel, P. S. Low, and C. P. Leamon Preclinical pharmacokinetics, tissue distribution, and antitumor activity of a folate-hapten conjugate-targeted immunotherapy in hapten-immunized mice Mol. Cancer Ther., December 1, 2006; 5(12): 3258 - 3267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hasegawa, T. Nakamura, M. Harvey, Y. Ikeda, A. Oberg, M. Figini, S. Canevari, L. C. Hartmann, and K.-W. Peng The Use of a Tropism-Modified Measles Virus in Folate Receptor-Targeted Virotherapy of Ovarian Cancer. Clin. Cancer Res., October 15, 2006; 12(20): 6170 - 6178. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
